DTC Pre-Review Guidance Could Make Promotional Campaigns More Costly
This article was originally published in The Pink Sheet Daily
PhRMA’s assistant general counsel says that FDA’s draft might increase expenses because of the need to submit final ads in advance and the potential to be asked for extensive revisions.
You may also be interested in...
The Senate measure adds a provision on breakthrough therapies and specifies that accelerated approval provisions do not alter substantial evidence standard used to approve drugs.
The agency’s draft guidance on prereview of television advertisements also requires companies to submit the information they rely on to support claims in an ad.
Certain drug classes will be required to submit certain types of ads, according to Tom Abrams, director of CDER’s recently elevated Office of Prescription Drug Promotion, but specifics will await the guidance itself.